Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas^[*]

Summary

Current data suggests that the risk of venous thromboembolism (VTE) in patients with non-Hodgkin lymphoma (NHL) is comparable to that observed in patients with solid tumours, although more robust confirmatory analyses are required. With that in mind, we investigated the occurrence of VTE in a pooled analysis of 12 “Fondazione Italiana Linfomi” (FIL) prospective clinical studies. Specifically, we wished to assess the cumulative incidence of VTE in NHL patients, evaluate the predictive value of the Khorana Score (KS), and identify other potential risk factors for VTEs. Data for VTE occurrence were retrieved from study databases and pharmacovigilance reports. Our analysis includes 1717 patients from 12 prospective phase II and III trials, including newly diagnosed NHL. We observed 53 VTEs (any grade) in 46 patients, with 20 severe VTEs in 17 patients. The cumulative incidences for „all-grade” or grade ≥3 VTEs were 2.9% (95% CI: 2.1–3.8) and 1.1% (95% CI: 0.6–1.6), respectively. KS categories were positively associated with the risk of VTE of any grade, and with severe events (i. e. grade ≥3; Gray’s test p-values = 0.048 and 0.012, respectively). Among NHL patients, those with diffuse large B-cell lymphoma (DLBCL) showed a greater risk of (any grade) VTE (HR: 3.42, 95% CI: 1.32–8.84, p-value = 0.011). Our study indicates that 1) VTE is a relevant complication for NHL patients, 2) KS is predictive of VTE events and 3) DLBCL histotype is an independent risk factor for VTE incidence, for which preventative interventions could be considered.

Supplementary Material to this article is available at www.thrombosis-online.com.

Keywords

Venous thromboembolism - non-Hodgkin lymphoma - Khorana Score

^* Preliminary results were presented in abstract form at the 2015 ASH meeting (Orlando, FL, USA), at the 2016 EHA meeting (Copenhagen, Denmark, EU),and at the 8th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2016 (Bergamo, Italy, EU).

• References

• 1 Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancies. Int J Hematol 2001; 73: 137-144.
• 2 Donati MB. Thrombosis and cancer: a personal view. Thromb Haemost 2007; 98: 126-128.
• 3 Korte W. Cancer and thrombosis: an increasingly important association. Support Care Cancer 2008; 16: 223-228.
• 4 Alcalay A. et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112-1118.
• 5 Chew HW. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
• 6 Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 2005; 51: 150-157.
• 7 Sutherland DE, Weitz IC. et al. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 43-52.
• 8 Kakkar AK. Thrombosis and cancer. Hematol 2004; J 5: S20-23.
• 9 Napolitano M. et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32: 3607-3612.
• 10 Oken MM. et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982; 05: 649-655.
• 11 Mahajan A. et al. Lymphoma and venous thromboembolism: influence on mortality. Thrombosis Res 2014; 133: S23-S28.
• 12 Melillo L. et al. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117: 215-220.
• 13 Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 48-57.
• 14 Ku GH. et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113: 3911-3917.
• 15 Kwaan HC, Vicuna B. Incidence and pathogenesis of thrombosis in hematologic malignancies. Semin Thromb Hemost 2007; 33: 303-312.
• 16 Caruso V. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216-2222.
• 17 Blom JW. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
• 18 Athale U, Siciliano S. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008; 51: 792-797.
• 19 Park LC. et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population”. Thrombosis Res 2012; 130: e6-e12.
• 20 Caruso V. et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18018 patients and 1149 events. Blood 2010; 115: 5322-5328.
• 21 Khorana AA. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 490-497.
• 22 http://www.nci.nih.gov/CTCAE/CTCAE4.0 – version 2016.
• 23 Gooley TA. et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators”. Stat Med 1999; 18: 695-706.
• 24 Fine JP, Gray RY. A proportional hazard model for the subdistribution of a competing risk. Am Stat Assoc 1999; 94: 496-509.